Testing atacicept for multiple kidney diseases
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a medicine called atacicept in adults and children with several types of kidney disease. The goal is to see if it can reduce protein in the urine and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must weigh at least 40 kg (about 88 lbs).
- You must have one of these kidney diseases: IgA nephropathy, IgA vasculitis with kidney involvement, primary membranous nephropathy, minimal change disease, focal segmental glomerulosclerosis, or primary nephrotic syndrome.
- Your blood pressure should be controlled (top number 160 or lower, bottom number 90 or lower).
- You need to be on a stable standard treatment plan for your kidney disease.
- You must not have an active viral or bacterial infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (FXS6837) for people with IgA nephropathy (a kidney disease that causes protein in the urine and can lead to kidney damage). The goal is to see if it can reduce protein loss and protect kidney function.
This study looks at the long-term safety and effectiveness of atacicept in people with IgA nephropathy (IgAN) who have already completed treatment in a previous atacicept study. It is for patients who want to continue their care and see how well the medicine works over more time.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
This trial tests an investigational medication for two rare kidney conditions that cause inflammation and protein in the urine. It aims to see if the drug is safe and helps control the disease, potentially slowing kidney damage.
This trial tests if avacopan, a targeted anti-inflammatory drug, can safely treat a severe form of IgA nephropathy (IgAN) where small crescents form in the kidney filters. It may help reduce protein leakage and preserve kidney function.
This trial tests a medication called atrasentan to see if it helps protect kidney function in people with IgA nephropathy, a kidney disease. It may slow down kidney damage and reduce protein in the urine.
Hear when a new IgAN trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.